About Nu Vision
Nu Vision is a company based in Nottingham (United Kingdom) founded in 2015. Nu Vision has raised $13.39 million across 6 funding rounds from investors including Mercia, Newable and The University of Nottingham. Nu Vision offers products and services including Omnigen and OmniLenz. Nu Vision operates in a competitive market with competitors including Imbed Biosciences, MiMedx Group, Cresilon, Kane Biotech and BioTissue, among others.
- Headquarter Nottingham, United Kingdom
- SectorsHealthcare
- Website nu-vision.co.uk
- Social LinkedIn X Facebook YouTube
- Legal Name Nuvision Biotherapies Limited
- Total Equity Funding$13.39M (USD)
in 6 rounds
- Latest Funding Round$6.57M (USD), Series B
Feb 2026
- InvestorsMercia
& 7 more
Products & Services of Nu Vision
Nu Vision offers a comprehensive portfolio of products and services, including Omnigen and OmniLenz.
Natural amniotic membrane dressing for ocular wound healing and recovery.
Bespoke lens for rapid, surgery-free ocular care and treatment.
Apps and channels of Nu Vision
its YouTube channel NuVision Biotherapies has 63 subscribers and 18 videos.
Videos from Nu Vision
The most watched videos on Nu Vision's YouTube channel, NuVision Biotherapies (63 subscribers). Click a video to play it here.
More on NuVision Biotherapies.
Funding Insights of Nu Vision
Nu Vision has successfully raised a total of $13.39M across 6 strategic funding rounds. The most recent funding activity was a Series B round of $6.57 million completed in February 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $13.39M
- Total Rounds 6
- Last Round Series B — $6.57M
- First Round $590,000
(Jul 2015)
- Investors Count 8
All 6 funding rounds of Nu Vision with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2026 | $6.57M | Series B | – | Mercia Ventures | |
| Mar 2023 | $1.31M | Series A | – | The University of Nottingham | |
| Jul 2021 | $2.49M | Series A | – | – | |
| Sep 2019 | $1.73M | Seed | – | Mercia, BioCity | |
| Feb 2018 | $695,739 | Seed | – | Mercia, Nottingham Technology Ventures | – |
| Jul 2015 | $590,000 | Seed | – | Mercia | – |
8 investors in total: 8 institutional.
Investors in Nu Vision
Nu Vision has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Mercia, Newable and The University of Nottingham.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment funding is provided to support Midlands SMEs growth. | – | meif.co.uk | Sheffield, United Kingdom | |
- | – | thepioneergroup.com | - | |
Life Science focused startup accelerator and incubator | 2002 | biocity.co.uk | Nottingham, United Kingdom | |
- | – | nottinghamtechventures.com | - | |
- | – | merciaventures.co.uk | - | |
Investment management services are provided by Mercia to various clients. | 1982 | mercia.co.uk | - | |
Undergraduate and postgraduate courses are offered across various disciplines. | 1948 | nottingham.ac.uk | Nottingham, United Kingdom | |
Business loans are provided to UK enterprises by Newable. | 1982 | newable.co.uk | London, United Kingdom |
Investor details for Nu Vision
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Nu Vision
12 people are tracked at Nu Vision (4 in leadership, 2 in board & advisors, 6 in team).
| Name | Role | Group |
|---|---|---|
Noel Waters | COO | Leadership |
Andrew Hopkinson | Founder & Chief Scientific Officer | Leadership |
Andy Hill | Chief Executive Officer | Leadership |
Tonicha Spencer | Head of UK Sales & Clinical Support | Leadership |
Roger Teasdale | Independent Non-Executive Director | Board & advisors |
Dushyant Mital | Medical Advisor | Board & advisors |
Adrian Del Arenal | Operations Manager & Designated Individual | Team |
Emily Britchford | Medical Affairs Officer | Team |
Rohit Bodalikar | Hospital Account Manager | Team |
Geert Kuit | Regulatory & Scientific Affairs Manager | Team |
Marson Kwan | Process Development Engineer | Team |
Michelle Jackson | Key Account Manager | Team |
Complete people profiles for Nu Vision
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Nu Vision
3 dated milestones of Nu Vision across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Nu Vision is founded.
- Funding First funding round of $590K.
- Funding Latest funding round, Series B, of $6.6M.
Competitors of Nu Vision
Nu Vision operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Imbed Biosciences, MiMedx Group, Cresilon, Kane Biotech and BioTissue, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| imbedbio.com | 2010 | Madison, United States | $22.7M | 35 | Nanotech-based wound care products are developed and provided. | |
| mimedx.com | 1985 | Marietta, United States | – | 735 | Regenerative biomaterial products and bioimplants for wound, surgical, sports medicine and orthopedics | |
| cresilon.com | 2010 | New York, United States | $106.67M | 73 | Developer of hemostatic products for wound care | |
| kanebiotech.com | 2001 | Winnipeg, Canada | – | – | Therapeutic solutions for biofilm prevention and removal are developed. | |
| biotissue.com | 2001 | Miami, United States | $110.04M | 234 | Regenerative biologic therapies for eye care are developed and provided. | |
| alafairbiosciences.com | 2011 | Austin, United States | $13.74M | – | Biomaterials and devices for internal wound healing are developed. | |
| lohmann-rauscher.com | 1998 | Rengsdorf, Germany | – | – | Dressing materials and medical devices | |
| sweetbio.com | 2015 | Memphis, United States | $16.92M | – | Wound-healing therapies for oral surgery and chronic wounds are developed. |
Detailed competitors of Nu Vision
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Nu Vision
The website of Nu Vision (nu-vision.co.uk) receives about 2.3K visits a month.
- Monthly visits2.3K
▲ 13.8% vs previous month
Latest news on Nu Vision
Complete news archive for Nu Vision
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Nu Vision
10 companies that operate in the same segment as Nu Vision (Wound Care), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanotech-based wound care products are developed and provided. | 2010 | Madison, Wisconsin, United States | USD 22.7 M | – | 35 | |
Fish-skin acellular dermal matrix technology is provided for wound treatments. | 2007 | Isafjordur, Iceland | USD 93.11 M | – | 150 | |
Developer of advanced haemostat and wound care dressing products | 2008 | Ahmedabad, Gujarat, India | USD 42.71 M | USD 2.88 M | 70 | |
Oxygen-based wound therapy devices are developed for healing non-healing wounds. | 2003 | Waterbeach, Cambridgeshire, United Kingdom | USD 68.39 M | – | – | |
Regenerative biomaterial products and bioimplants for wound, surgical, sports medicine and orthopedics | 1985 | Marietta, Georgia, United States | – | USD 418.63 M | 837 | |
Biological drugs for skin and mucosa wound treatment are developed. | 2016 | Uppsala, Uppsala County, Sweden | USD 4.02 M | USD 1.12 M | – | |
Developer of hemostatic products for wound care | 2010 | New York, New York, United States | USD 113.35 M | – | – | |
Regenerative therapies for wound care are developed and commercialized. | 1985 | Canton, Ohio, United States | USD 30 M | USD 564.17 M | 869 | |
Cold plasma solutions for wound treatment are developed. | 2013 | Eindhoven, Noord-brabant, Netherlands | USD 7.06 M | – | – | |
Point-of-care devices for wound bacterial assessment are provided. | 2013 | Toronto, Ontario, Canada | USD 43.2 M | – | 49 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Nu Vision
Nu Vision was founded in 2015.
Nu Vision is headquartered in Nottingham, United Kingdom.
Nu Vision is a funded company, having raised a total of $13.39M across 6 funding rounds to date. The company's 1st funding round was a Seed of $590K, raised on Jul 2015.
NuVision was founded in 2015 in Nottingham, United Kingdom, within the biotechnology sector focused on ophthalmic care. Regenerative wound dressings are developed for the eyes surface, including Omnigen, a dry preserved biological matrix derived from human amniotic membrane used in wound care. An OmniLenz bandage contact lens is also provided for suture-free transplantation. Operations center on biological matrix preservation and application in eye regeneration.
Nu Vision's top competitors include Imbed Biosciences, MiMedx Group and Cresilon.
Nu Vision offers Omnigen and OmniLenz.
Nu Vision has 8 investors. Key investors include Mercia, Newable, The University of Nottingham, BioCity, and Midlands Engine Investment Fund.
Nu Vision operates through Nuvision Biotherapies Limited.